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Abstract
Background: Autism spectrum disorder (ASD) is reported in 30 to 60% of patients with tuberous sclerosis complex
(TSC) but shared genetic mechanisms that exist between TSC-associated ASD and idiopathic ASD have yet to be
determined. Through the small G-protein Rheb, the TSC proteins, hamartin and tuberin, negatively regulate
mammalian target of rapamycin complex 1 (mTORC1) signaling. It is well established that mTORC1 plays a pivotal
role in neuronal translation and connectivity, so dysregulation of mTORC1 signaling could be a common feature in
many ASDs. Pam, an E3 ubiquitin ligase, binds to TSC proteins and regulates mTORC1 signaling in the CNS, and the
FBXO45-Pam ubiquitin ligase complex plays an essential role in neurodevelopment by regulating synapse formation
and growth. Since mounting evidence has established autism as a disorder of the synapses, we tested whether rare
genetic variants in TSC1, TSC2, MYCBP2, RHEB and FBXO45, genes that regulate mTORC1 signaling and/or play a role
in synapse development and function, contribute to the pathogenesis of idiopathic ASD.
Methods: Exons and splice junctions of TSC1, TSC2, MYCBP2, RHEB and FBXO45 were resequenced for 300 ASD trios
from the Simons Simplex Collection (SSC) using a pooled PCR amplification and next-generation sequencing strategy,
targeted to the discovery of deleterious coding variation. These detected, potentially functional, variants were
confirmed by Sanger sequencing of the individual samples comprising the pools in which they were identified.
Results: We identified a total of 23 missense variants in MYCBP2, TSC1 and TSC2. These variants exhibited a near equal
distribution between the proband and parental pools, with no statistical excess in ASD cases (P > 0.05). All proband
variants were inherited. No putative deleterious variants were confirmed in RHEB and FBXO45. Three intronic variants,
identified as potential splice defects in MYCBP2 did not show aberrant splicing upon RNA assay. Overall, we did not
find an over-representation of ASD causal variants in the genes studied to support them as contributors to autism
susceptibility.
Conclusions: We did not observe an enrichment of rare functional variants in TSC1 and TSC2 genes in our sample set
of 300 trios.
Keywords: Autism spectrum disorder, Tuberous sclerosis complex, Mammalian target of rapamycin, Next-generation
sequencing, Rare variants
Background
Autism spectrum disorders (ASDs) are a heterogeneous
group of neurodevelopmental disorders characterized by
impairments in reciprocal social communication and
stereotyped behaviors. Though the genetic causes of ASD
are diverse [1], mutations in many ASD genes, including
NRXN1, NLGN3/4 and SHANK2/3, are associated with
altered synaptogenesis, establishing aberrant synaptic
protein synthesis and/or synaptic function as a common
underlying mechanism in ASD [2,3]. Single gene Mendelian
disorders such as tuberous sclerosis complex (TSC),
fragile X syndrome (FXS), Rett’s syndrome and Angelman
syndrome show a high prevalence of autism [4]. An
understanding of the underlying mechanisms of autism in
such single gene disorders may offer insights into the
pathogenesis of idiopathic ASD. TSC, characterized by
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mutations in either of the two tumor suppressor genes
encoding hamartin (TSC1) and tuberin (TSC2). Features
of ASD are present in 30 to 60% of individuals with TSC
[5]. Hamartin and tuberin form a complex that functions
as a critical negative regulator of mammalian target of
rapamycin complex 1 (mTORC1)-mediated signaling [6,7].
The TSC proteins act as a central hub in relaying
signals from diverse cellular pathways to control mTORC1
activity (Figure 1). mTORC1 signaling in neuronal
translation has been established as a regulator of long-
lasting synaptic plasticity and memory as it integrates
signals from many neuronal surface receptors/channels
via ERK- and PI3K/Akt-mediated phosphorylation of
the TSC1-TSC2 complex. Translational control is also
essential for neuronal functions such as growth and
axon guidance [8]. Furthermore, aberrant activation of
mTORC1 signaling is a common feature in syndromes
associated with autistic phenotypes and cognitive
impairments such as TSC, fragile-X, neurofibromatosis-1
(NF1) as well as those with PTEN mutations seen in ASD
with macrocephaly [9].
Consequently, we hypothesized that aberrant mTORC1
signaling may be a shared pathway between syndromic
ASD and non-syndromic ASD, and that rare functional
variants in genes that regulate mTORC1 signaling and/or
play a role in synapse development and function may be
associated with ASD. In this study, we chose TSC1, TSC2,
MYCBP2, RHEB and FBXO45 as candidate genes for non-
syndromic ASD and carried out resequencing in 300 ASD
trios from the Simons Simplex Collection (SSC) using next-
generation sequencing (NGS) technology. The rationale for
the selection of these genes is based on their critical roles
in neurodevelopment as briefly described below.
Loss of a single copy of Tsc1 in the mouse results in
defects in neuronal morphology, including increased
soma size, decreased spine density and increased spine
size, thus implicating TSC proteins in synapse function
in neurons [10]. Mice with a heterozygous inactivating
mutation in Tsc2 exhibit abnormal hippocampal CA1
long-term potentiation (LTP), and consequently deficits
in hippocampal-dependent learning [11]. Treatment
with rapamycin, a specific inhibitor of mTORC1 can
improve neuronal hypertrophy and improve behavioral
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Figure 1 A model of TSC/mTORC1 signaling pathway at the neuronal synapse. Tuberin (TSC2) and hamartin (TSC1) act as central players in
mTORC1 signaling to regulate neuronal/synaptic activity. Neurotrophic (NT) factors such as BDNF, as well as synaptic activity initiate mTORC1
signaling via receptors (Rc) including neurotrophic Rc and glutamate receptors including NMDA Rc and mGluR Rc. The mTOR candidate genes
resequenced in the study are shown in red. Ub, ubiquitin; P, phosphorylation.
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+/− mutant mice [11]. Recent studies re-
port rare variants in TSC1 and TSC2 genes to be associated
with idiopathic ASD [12,13].
The small GTPase Rheb (Ras homology enriched in brain)
is a direct target of tuberin and hamartin in both Drosophila
and mammals [14,15]. Rheb is highly expressed in the
hippocampus and is rapidly induced by growth factors
and receptor-dependent synaptic activity, suggesting
that Rheb may play an essential role in long term activity-
dependent neuronal response [16]. We hypothesized
that gain of function mutations in RHEB,r e s u l t i n gi n
aberrant mTORC1 activation and synaptic connectivity
may occur in ASD.
We previously identified Pam (MYCBP2)a sa ni n t e r a c t o r
of the TSC protein complex in the mammalian CNS [17].
Human Pam and its homologs (the PHR family of
proteins), including Phr1 in mouse, Highwire (HIW) in
Drosophila, Regulator of Presynaptic Morphology (RPM-1)
in Caenorhabditis elegans,a n dE s r o mi nz e b r a f i s h ,a r eE 3
ubiquitin ligases that have emerged as key regulators of
axon guidance, outgrowth and synapse development [18].
Our studies show that Pam interacts with the TSC1-TSC2
complex, and regulates mTORC1 signaling [17,19,20].
FBXO45, an F-box protein restricted to the nervous system,
is required for normal neuromuscular synaptogenesis,
axon pathfinding and neuronal migration. Proteomic
analysis has revealed that FBXO45 specifically associ-
ates with Pam, forming a novel FBXO45-Pam ubiquitin
ligase complex that plays an important role in neural
development [21].
Methods
ASD subjects
We obtained lymphoblast cell line DNA samples from
300 ASD trios through the Simons Simplex Collection
(SSC), a resource of the Simons Foundation Autism
Research Initiative (SFARI) [22]. DNAs from the de-
identified subjects used in this study were obtained,
with the institutional review board approval of Partners
HealthCare System, from the Rutgers University Cell
and DNA Repository. DNAs and cell lines deposited
into this public repository, to further ASD research as
part of the SSC, were all from affected subjects and
unaffected family members who provided informed
consent through the SFARI and its twelve participating
institutions (Baylor College of Medicine, Children's
Hospital Boston, Columbia University, Emory University,
McGill University, University of California, Los Angeles,
University of Illinois at Chicago, University of Michigan,
University of Missouri, University of Washington,
Vanderbilt University and Yale University), based upon
protocols approved by each institutional review board.
The SSC families included in the study are provided in
Additional file 1: Table S1.
Next-generation sequencing
Genomic DNA pooling strategy
DNA concentration was measured by Quant-iT
™
PicoGreen
W dsDNA reagent (Invitrogen, Carlsbad, CA,
USA) and normalized to 4 ng/μLb ym u l t i p l er o u n d so f
quantification and dilution. A 10% variance was allowed,
as that is the limit of quantitation of PicoGreen
W detection
system [23]. A pooling strategy was employed to process
the 300 SSC trios wherein 10 pools of probands (30
samples per pool), and 10 pools of parents (60 samples per
pool comprising 30 mothers and 30 fathers for each
corresponding proband) were assembled (Additional file 2:
Figure S1). Samples were pooled after multiple rounds of
quantification and normalization, as described earlier [23],
to ensure that the DNA pool accurately reflected sample
allele frequency. No other experiments were performed to
examine the sample coverage directly.
Target amplification and PCR pools
Primers were designed for all coding exons of TSC1,
TSC2, MYCBP2, RHEB and FBXO45 using Primer3
software on the hg19 reference sequence (amplicons of
200 to 600 base pairs (bp) including approximately 100
bp of intronic sequence flanking either side of each
exon; exons exceeding 600 bp were split into two or
more overlapping amplicons). All amplicons were tested
on three HapMap CEPH (CEU) samples. To provide a
recognition site for downstream concatenation, NotI tails
(5' CGCGTTGCGGCCGC 3') were added to the primer
ends. The details of the primers designed for the five
genes are provided in Additional file 3: Table S2. Target
regions were PCR amplified using PfuUltra II
™ Fusion
HS DNA polymerase (Agilent Technologies, Santa Clara,
CA, USA) for all the 20 DNA pools assembled. Following
amplification, a representative subset of PCR amplicons
(for each DNA pool) was visualized by agarose gel electro-
phoresis for confirmation/quality control. The PCR ampli-
fication products were again quantified by PicoGreen
W,
normalized and pooled, yielding PCR pools containing
equal concentrations of PCR amplicons from all exons of
each candidate gene.
Library preparation and high throughput sequencing
As described by Calvo et al.[ 2 4 ] ,p r o d u c t sw e r e
concatenated following amplification, size selected
(> 600 bp), and randomly sheared using a Covaris S2
system (Covaris, Inc., Woburn, MA, USA) into fragments
ranging from 150 to 200 bp in length. Following Illumina
paired-end library preparation of the sheared products
(Illumina, San Diego, CA, USA), the final libraries
were quantified by PicoGreen
W (Quant-iT, Invitrogen,
Carlsbad, CA, USA), Agilent Bioanalyzer DNA 1000
kit (Agilent Technologies, Santa Clara, CA, USA), and
Quantitative PCR (qPCR) analysis with iQ SYBR Green
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qPCR was performed with primers targeting the
Illumina adaptor oligos and an Illumina PhiX sample
serially diluted for a standard curve, thereby quantifying
only DNA fragments containing properly ligated adaptor
oligos required for sequencing. For additional quality
control, some of the libraries were cloned into a sequencing
vector using Zero Blunt
W TOPO
W PCR Cloning Kit
(Invitrogen, Carlsbad, CA, USA), and representative
individual clones were sequenced (using conventional
Sanger method) to verify the presence of candidate
gene exons within the libraries. 76 bp reads were aligned
to the genome using Novoalign (Novocraft, Selangor,
Malaysia) and mutation analysis was performed with the
Genome Analysis Toolkit [25,26] and Syzygy [23].
Confirmation of identified variants
Confirmation of the potentially deleterious variants
identified was performed by Sanger sequencing on an ABI
3730 capillary sequencer and DNA sequence analysis was
performed using Sequence Scanner software version 1.0
(Applied Biosystems, Foster City, CA, USA). PCR primers
used for sequencing were the same as those used for amp-
lification of exons from sample pools except for the NotI
tails. We also tested all the confirmed proband variants in
the corresponding parental pools and all the confirmed
parental variants in the corresponding proband pools.
Variant analyses
The significance of differences in the number of variants
occurring between ASD cases and parents was tested using
Fisher’s exact test, with nominal statistical significance
defined as a two-sided P < 0.05. The potential consequence
on protein function of each confirmed missense variant
was evaluated using PolyPhen-2 software [27]. The branch
point sequence analysis module of the Human Splicing
Finder Version 2.4.1 was used to identify potential
splicing defects [28]. Default settings were used for all
prediction programs.
Testing intronic variants for exon skipping
Total RNA was isolated using RNeasy Mini kit (Qiagen
Sciences, Germantown, MD, USA) according to the
manufacturer’s instructions. RNA quantity and quality were
measured by ND-1000 (Nanodrop, Thermo Scientific,
Lafayette, Co, USA). First strand cDNA was generated
using SuperScript
™ II reverse transcriptase according to
the manufacturer's instructions (Invitrogen, Carlsbad,
CA, USA). MYCBP2 intronic variants were tested for
exon skipping using the following cDNA primer
pairs: (a) 5' ACCACAGCATGACAGCCATA 3' and 5'
GCAAGTCCTTTTCCAGATCG 3' for variant c.1625-
19T>C, (b) 5' TGGCAGCTATGCAGGACTTA 3' and 5'
TGCAAGAAGGTCACCATCAG 3' for variant c.3982
+31C>G and (c) 5' TTCATTGGAGACTGCATCAGA 3'
and 5' TGCAGCCTCCTCAAGAATTT 3' for variant
c.6727-16T>C.
Results
We sequenced the coding regions of five candidate
genes that regulate mTORC1 signaling and/or are
implicated in synapse development and function (TSC1,
TSC2, MYCBP2, RHEB and FBXO45) in 300 ASD trios
from the SSC. We combined DNA from the 300 trios
into 10 pools of 30 ASD probands and 10 pools of the
corresponding 60 parents (Additional file 2: Figure S1).
Each pool was PCR amplified to capture the 155 coding
exons from the five target genes (Table 1). RHEB exon 1
and the first 125 bases of FBXO45 exon 1 could not be
successfully amplified and hence are not included in the
study. The 165 successful PCR amplicons were combined,
concatenated and sheared to construct libraries. The 20
libraries were sequenced using the Illumina Genome
Analyzer (Illumina, San Diego, CA, USA).
Sequencing yielded relatively uniform coverage distri-
bution of each exon across all five candidate genes and
20 pools. A representative example of the uniform
sequencing coverage obtained is depicted in Figure 2 for
two of the largest genes sequenced, MYCBP2 (83 coding
exons) and TSC2 (41 coding exons) for two proband
pools and their corresponding parental pools. For all
coding exons, read depth averaged at least 15,000x for
each pool, or 200x for each individual proband/parent
sample. Overall, sequence coverage was obtained from
99.4% of all targeted exons and 99.8% of all targeted
bases (Table 1). Additional file 4: Table S3 provides the
mean and range of sequence coverage over each exon
for the five genes examined, with data for each proband
and parental pool shown separately. Also, we were able to
detect and confirm one variant in a pool of 30 samples
(3.33% sensitive) and one variant in a pool of 60 samples
(1.66% sensitive) by the analytical tools used.
After filtering for high quality variant calls using
Syzygy [23], the variants were classified for analysis by
(1) type/location, into nonsense, coding non-synonymous
(missense), coding synonymous, intronic, 3'-UTR, 5'-UTR,
and 5'- and 3'- splice variants, (2) distribution, into proband
(proband pool only),‘inherited’ (proband and corresponding
parental pool) and non-transmitted (parental pool only)
variants, and (3) presence/absence in either the dbSNP or
1000 Genomes databases, into reported and novel variants.
We prioritized those proband, inherited or parental coding
variants, not previously reported in the public databases
that produced a premature stop codon (nonsense) or other
non-synonymous change, as well as intronic variants that
had a potential role in altering splicing based upon branch
point sequence analysis (see Methods). The selected
variants were confirmed by Sanger di-deoxy sequencing of
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the variant was identified.
Notably, there were no confirmed de novo events in
the probands or inherited nonsense variants in any of the
five genes. A total of ten missense and three non-coding
intronic variants in MYCBP2, three missense variants in
TSC1 and ten missense variants in TSC2 were confirmed.
There were no confirmed variants of interest based on the
above criteria in FBXO45 and RHEB. A recent study,
which examined the metabotropic glutamate-receptor
(mGluR) signaling pathway genes for rare genetic variants
contributing to autism susceptibility also, did not find any
significant coding variants in RHEB [12].
Of the ten missense variants confirmed in MYCBP2,f o u r
(K1325R, I1581V, D2437N and N2811D) were observed as
variants inherited by the proband from a parent. The
remaining six variants (V534I, K543R, V1285I, F1849C,
P2533L and R2803H) were identified in different parent
Table 1 Coverage summary of mTOR pathway candidate genes sequenced by next generation sequencing
Gene Chromosome Exons screened Targeted
exon bases
High coverage
bases
a
Average coverage
per pool
Average coverage
per proband
b
Average coverage
per parent
b
TSC1 9 Exons 3-23 3495 3495 52804.6 1760.2 880.1
TSC2 16 Exons 1-41 5355 5355 79732.3 2657.7 1328.9
RHEB 7 Exons 2-8 555 503 16050.2 535 267.5
MYCBP2 (Pam) 13 Exons 1-83 13923 13923 21906.8 730.2 365.1
FBXO45 3 Exons 1-3 861 858 33853.7 1128.5 564.2
aindividual bases for which at least 3000x average coverage was obtained.
bstatistics reflect coverage per proband/parent sample, not per chromosome.
Figure 2 Schematic representation of the sequence coverage data. Coverage plots, represented by blue peaks, are shown for two of the
largest genes studied, MYCBP2 (83 exons, upper panel) and TSC2 (41 exons, lower panel). Intron-exon structure of the genes is shown along with
sequencing coverage for each exon for proband pools 1 and 2 (PP1, PP2) and their corresponding parental pools (CP1, CP2). The coverage plots
were generated using The Integrative Genomics Viewer at Broad Institute [29].
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The inherited variant K1325R and non-transmitted
variant V534I were both found in the father of a single
trio (Table 2). The three intronic variants (c.1625-19T>C,
c.3982+31C>G and c.6727-16T>C) confirmed in MYCBP2
were all inherited (Table 2). None occurred at a classic
donor/acceptor site but they were suspected instead to
represent potential splicing defects due to their occurrence
at putative branch/polypyrimidine sites. However, no
exon skipping was observed for any of the three vari-
ants when the respective RNA samples were analyzed
(data not shown).
For the TSC genes, we confirmed two inherited
missense variants (T360N and P448S) in TSC1 and six
(I64V, H152D, K533Q, K954R, E984Q and A1429S) in
TSC2. Four of these (TSC1: T360N, P448S; TSC2:
K533Q, Q984N) have been previously reported as potential
risk factors for ASD [12,13]. We also identified one non-
transmitted parental missense variant (L116V) in TSC1 and
four (C728F, P878S, S960F and T1330M) in TSC2 (Table 3).
Two independent studies have reported differing roles for
the TSC1 L116V variant, as an ASD specific variant [12]
and as a control variant [13], though it appears here to be a
rare polymorphism (Table 3). All the three TSC1 variants
(inherited variants T360N and P448S, and non-transmitted
variant L116V) are also reported in the tuberous sclerosis
database - Leiden Open Variation Database (LOVD, http://
chromium.liacs.nl/LOVD2/TSC/home.php) - as probably
non-pathogenic. However, all the TSC2 variants excepting,
A1429S and T1330M are novel (Table 3). The variants
T360N in TSC1 and A1429S in TSC2 were detected in
both parents; however, the respective probands were
heterozygous for these changes (Table 3).
As an additional large scale control dataset, we used data
from the National Heart, Lung, and Blood Institute exome
variant server (NHLBI EVS) and found five variants in
MYCBP2 (V534I, K543R, V1285I, R2803H and N2811D),
all three TSC1 variants (L116V, T360N and P448S) and a
single TSC2 variant (A1429S) to be reported in the controls
(Tables 2 and 3).
Overall, we did not find a significant enrichment of
rare inherited variants in ASD probands as compared
to the non-transmitted variants in parents for MYCBP2
(P > 0.05) or the TSC genes (P > 0.05).
An additional review of TSC missense mutations
reported in LOVD with NHLBI EVS suggested that 19
TSC1 and 56 TSC2 variants were seen in controls.
Furthermore, missense variants in TSC genes reported
to have functional impact [30-32] were catalogued and
found not to be seen in idiopathic ASD cases, suggesting
that mutations observed in frank TSC are not seen in
ASD (Additional file 5: Table S4).
Discussion
Dysregulation of mTORC1 signaling is correlated with
aberrant synaptic protein synthesis and has emerged as a
common biochemical pathway in many syndromes
associated with ASD. Because approximately 50 to 60%
Table 2 Details of rare variants identified in MYCBP2 in ASD cases and parents
SSC Proband/ Parent ID
a Variant type Coordinate
b Amino acid position
c Inheritance Functional prediction
by polyphen-2
Exome variant
server
d
Inherited coding sequence variants
11664.p1 missense 77764453 K1325R paternal damaging -
11441.p1 missense 77755922 I1581V maternal benign -
11002.p1 missense 77714277 D2437N maternal damaging -
11000.p1 missense 77672744 N2811D maternal benign reported
Non-transmitted coding sequence variants
11664.fa missense 77835444 V534I - benign reported
11587.fa missense 77835416 K543R - benign reported
11573.mo missense 77765917 V1285I - benign reported
11149.fa missense 77745761 F1849C - benign -
11765.mo missense 77700625 P2533L - benign -
11775.mo missense 77672767 R2803H - benign reported
Intronic variants (potential splicing defects)
11242.p1 c.1625-19T>C 77838156 - paternal - -
11417.p1 c.3982+31C>G 77779577 - maternal - -
11291.p1 c.6727-16T>C 77738691 - maternal - -
ap1: proband; fa: father, mo: mother.
bcoordinates based on genome build hg19.
camino acid position based on Swiss-Prot accession # O75592.3.
dNHLBI exome variant server, Seattle, WA, USA.
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sized that functional rare variants in genes that regulate
mTORC1 signaling may be frequent in non-syndromic
ASD, which may explain the autistic phenotypes shared
between TSC and ASD in general. We investigated five
mTOR pathway candidates, TSC1, TSC2, MYCBP2,
RHEB and FBXO45, based upon their critical roles in
neurodevelopment. Mice lacking these genes exhibit
defects in synapse development, axon navigation and
hippocampal-dependent learning [20,21,33-35]. The find-
ings of our study however do not support the hypothesis
and suggest that rare variants in the studied mTOR
pathway candidate genes do not play a significant causal
role in autism. We did not detect support for a genetic
association between any of the studied genes and autism.
No de novo variations, considered to be a hallmark of the
risk-determining genes of greatest effect, were identified;
neither did we identify any nonsense variants. In MYCBP2,
TSC1 and TSC2, we observed a few rare inherited single
nucleotide variants in ASD probands, but a comparable
number of variants were also found in the parents indi-
cating that the ASD variants are probably rare private
sequence changes.
Next-generation sequencing of pooled samples is shown
to be efficient and cost-effective in capturing variation in a
limited target region that has been selectively amplified in
multiple DNA samples as shown in studies to identify
genes in type 1 diabetes, human complex 1 deficiency and
inflammatory bowel diseases [23,24,36]. The approach is
capable of deriving very deep coverage in targeted regions
and as such can be sensitive to the detection of rare or
private events within the pool [24]. However, it should be
noted that we chose to validate only the subset of presum-
ably deleterious and thus potentially pathogenic variants, a
strategy that was not specific to detection and confirmation
o ft h ef u l lm u t a t i o n a lb u r d e n .Nonetheless, our negative
findings are consistent with results from three recent stud-
ies that examined the patterns of de novo point mutations
in ASDs by whole exome sequencing [37-39]. None of the
three studies, all of which reported overlapping results with
respect to genes conferring susceptibility to autism,
identified the mTOR pathway genes that we investigated
as genuine autism risk factors, though de novo mutations
were identified in two of the genes, MYCBP2 and TSC2.
Neale et al. [37] identified a single de novo missense
mutation in the myc-binding domain of MYCBP2.
The mutation was however predicted to be benign by
PolyPhen-2. These findings do not rule out Pam (MYCBP2)
as a functional participant in autism as it is probable that
Pam, an E3 ubiquitin ligase, may be functioning only at
the translational level as evidenced by recent work from
our laboratory on mTORC1 regulation by Pam in the
brain using mouse models [20]. Pam has been identified
as a potential substrate whose phosphorylation is directly
or indirectly controlled by mTORC1 in two independent
phosphoproteome studies [40,41]. Furthermore, Pam has
also been identified as a target transcript of fragile X mental
retardation protein (FMRP) [42]. Both mTOR and FMRP
Table 3 Details of rare missense variants identified in TSC genes in ASD cases and parents
TSC gene SSC Proband/
Parent ID
a
Coordinate
b Amino acid
position
c
Inheritance Functional prediction
by polyphen-2
LOVD TSC database
d Exome variant
server
e
Inherited coding sequence variants
TSC1 11208.p1 135786451 T360N both damaging probably not pathogenic reported (0.0461)
TSC1 11409.p1 135782214 P448S paternal benign probably not pathogenic reported (0.3844)
TSC2 11232.p1 2100452 I64V paternal damaging - -
TSC2 11443.p1 2104414 H152D maternal benign - -
TSC2 11543.p1 2114426 K533Q maternal damaging - -
TSC2 11619.p1 2127622 K954R paternal benign - -
TSC2 11590.p1 2127711 E984Q paternal damaging - -
TSC2 11196.p1 2134508 A1429S both benign no known pathogenicity reported (0.2324)
Non-transmitted coding sequence variants
fTSC1 - 135800991 L116V - damaging pathogenicity unknown reported (0.0154)
TSC2 11780.fa 2122327 C728F - damaging - -
TSC2 11458.mo 2125886 P878S - damaging - -
TSC2 11303.mo 2127640 S960F - damaging - -
TSC2 11195.mo 2133801 T1330M - benign pathogenicity unknown -
ap1: proband; fa: father; mo: mother.
bcoordinates based on genome build hg19.
camino acid position based on Swiss-Prot accession # Q92574.2 and P49815.2 for TSC1 and TSC2, respectively.
dtuberous sclerosis database: Leiden Open Variation Database.
eNHLBI exome variant server, Seattle, WA, USA. Values in parentheses denote minor allele frequency in percent.
fidentified by next-generation sequencing but not tested by Sanger sequencing because it was previously reported.
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http://www.molecularautism.com/content/4/1/5Table 4 Inter-study comparison of TSC variants identified in ASD samples
Gene Amino acid position
a Current study Schaaf et al. [13] Kelleher et al. [12] Exome variant server
b
TSC1 P231L - - ASD variant -
TSC1 Q527R - - ASD variant -
TSC1 L116V parental variant control ASD variant reported (0.0154)
TSC1 M322T - - - reported (16.5462)
TSC1 S334L - control - reported (0.0308)
TSC1 R336W - control ASD variant reported (0.0231)
TSC1 T360N inherited variant proband/control - reported (0.0461)
TSC1 T393I - - ASD variant reported (0.0077)
TSC1 S403L - control - reported (0.0615)
TSC1 P448S inherited variant proband ASD variant reported (0.3844)
TSC1 G560S - control - -
TSC1 K587R - proband/control - reported (0.0923)
TSC1 Q654E - - ASD variant -
TSC1 H732Y - proband/control - reported (0.2691)
TSC1 N762S - proband - reported (0.0384)
TSC1 Q906H - - ASD variant -
TSC1 G1035S - proband/control - reported (0.1232)
TSC1 M1067L - proband - -
TSC2 S6N - control - -
TSC2 M50V - proband/control - reported (0.0231)
TSC2 I64V inherited variant yes - -
TSC2 E92V - control - reported (0.1466)
TSC2 A97T - control - -
TSC2 A145T - - ASD variant -
TSC2 H152D inherited variant - - -
TSC2 A431V - - ASD variant -
TSC2 A460T - proband/control - reported (0.0799)
TSC2 S487C - - ASD variant -
TSC2 K533Q inherited variant proband - -
TSC2 R537C - proband - reported (0.0462)
TSC2 I606V - proband - reported (0.0154)
TSC2 D635E - control - -
TSC2 V638M - - ASD variant -
TSC2 A678T - proband - reported (0.0162)
TSC2 Y719H - - ASD variant -
TSC2 C728F parental variant - - -
TSC2 P874L - - ASD variant reported (0.0077)
TSC2 P878S parental variant - - -
TSC2 F904A - proband/control - reported (0.0077)
TSC2 K954R inherited variant - - -
TSC2 S960F parental variant - - -
TSC2 E984Q inherited variant proband/control - -
TSC2 D1084E - - ASD variant -
TSC2 P1097L - proband - -
TSC2 A1141V - proband - reported (0.6389)
TSC2 S1276F - - ASD variant -
TSC2 P1305L - - ASD variant reported (0.7186)
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http://www.molecularautism.com/content/4/1/5play key roles in neuronal translation, and recent evidence
indicates a link between mTORC1 signaling and FMRP.
The role of Pam in regulating TSC/mTORC1 signaling in
neurons, and more importantly the regulation of Pam by
both mTORC1 and FMRP as well as the function of
Pam in synapse development, suggest that either a
direct or indirect involvement of this protein is possible in
a subset of ASD.
Mutations in the TSC genes,TSC1 and TSC2 are known
to cause syndromic autism [33]. In non-syndromic autism
patients, TSC rates of 1.1% to 1.3% have been reported in
many studies [43-47]. Two recent studies looked at the
possible role of TSC1 and TSC2 genes along with others
in non-syndromic autism [12,13]. Schaaf et al. [13]
introduced the concept of ‘oligogenic heterozygosity’
of coding non-synonymous variants as a novel patho-
genic mechanism for ASD risk. The study suggested
that groups of variants with smaller effects in multiple
genes acting together might be contributing to autism in
patients with near normal/normal IQs and non-syndromic
autism. Since our study did not examine the other
candidate genes included in that model, we believe
that we can neither support nor refute the ‘oligogenic
heterozygosity’ model. Kelleher et al. [12] found a
significant excess of TSC gene single nucleotide variants in
the AGRE (Autism Genetic Resource Exchange) samples
compared to controls. Table 4 summarizes TSC variants
identified by our study and those by Kelleher et al. [12] and
Schaaf et al. [13]. Of the 20 TSC variants identified as ASD
specific by Kelleher et al. [12], 7 variants (35%) are reported
i nt h eN H L B IE V S( T a b l e4 ) .A l s o ,o ft h e1 2v a r i a n t si d e n t i -
fied as seen only in ASD probands and not controls by
Schaaf et al. [13], 6 variants (50%) are reported in the
NHLBI EVS (Table 4), raising the question of whether these
variants produce pathogenic effects. A damaging de novo
mutation R1580W has been identified in the GAP-domain
of TSC2 in one of the recent autism exome sequencing
studies [39] raising the question as to whether a subclinical
TSC was present in that patient. The functional impact of
this variant however needs to be assessed.
Given that we have demonstrated our approach to be
sensitive to detection of a single private mutation in
each pool, our study has comparable or greater power to
detect an association of similar effect size to those
reported from de novo mutations in each of the previous
exome studies (Neale et al., n = 175 trios [37]; O'Roak
et al., n = 209 families [39]; Sanders et al.,n=2 3 8f a m -
ilies [38]). With 300 trios, we calculate that we have
approximately 80% power to detect a scenario where
2.5% of cases are caused by rare variants in TSC1 and
4.2% of cases are caused by rare variants in TSC2 at an
experiment-wide significance threshold.
In our study, because we found a comparable number
of transmitted and non-transmitted rare coding variants,
we cannot provide support for an important role of rare
variants in TSC genes in the pathogenesis of non-
syndromic autism. Exome sequencing data of 1,000 cases
and matched controls from Neale and Daly laboratories
have observed TSC1 missense variants that are predicted
to be damaging by PolyPhen-2 in 15 cases and 12 controls
and a similar ratio of TSC2 missense variants in 63 cases
and 60 controls (Daly M, unpublished data). This is
consistent with our observation and those of previous
exome sequencing studies that any ASD risk conferred by
TSC gene variants is likely to be modest.
Conclusions
Our results suggest that in this sample of 300 trios
ascertained, based on a proband with idiopathic ASD,
there is no significant enrichment of ASD-risk variants
in the candidate genes TSC1, TSC2, MYCBP2, RHEB
and FBXO45. We did not observe any de novo or non-
sense mutations with putative functional impact in any
of the genes studied. Consistent with the null hypothesis,
the number of rare missense variants transmitted to
ASD cases was comparable to the untransmitted vari-
ants. Missense variants in TSC genes reported to have
functional impact [30-32] are not observed in any of the
idiopathic ASD cases [12,13,37-39] including those from
our study and those in unpublished data from Neale and
Table 4 Inter-study comparison of TSC variants identified in ASD samples (Continued)
TSC2 G1325D - - ASD variant -
TSC2 T1330M parental variant - - -
TSC2 E1351K - - ASD variant -
TSC2 S1365L - control - reported (0.0077)
TSC2 R1369Q - proband -
TSC2 G1425R - proband - -
TSC2 A1429S inherited variant - - reported (0.2324)
TSC2 G1439D - - ASD variant reported (0.4412)
TSC2 S1448R - proband - -
aamino acid position based on Swiss-Prot accession # Q92574.2 and P49815.2 for TSC1 and TSC2, respectively.
bNHLBI exome variant server, Seattle, WA, USA. Values in parentheses denote minor allele frequency in percent.
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http://www.molecularautism.com/content/4/1/5Daly. It remains essential to examine the functional
impact of the missense variants detected in idiopathic
ASD to conclude as to whether rare functional variants
in TSC1/TSC2 could be a very rare cause of non-
syndromic autism. Our data do not necessarily under-
mine the potential functional role of mTORC1 signaling
in ASD. It remains possible that genes associated with
ASD will ultimately be linked directly or indirectly to this
pathway, known for its complexity, with many feed-forward
and feed-back regulatory features.
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Additional file 1: Table S1. Families from the Simons Simplex
Collection used in the study. SSC family IDs for all the 300 ASD trios
including affected probands and unaffected parents are provided.
Additional file 2: Figure S1. Schematic overview of the strategy used
for next generation sequencing of candidate genes in the mTOR
pathway. For the 300 ASD trios, DNA pooling was performed to prepare
proband pools (10 pools of 30 samples each) and parental pools (10
pools of 60 samples each). The coding exons of the target genes were
individually amplified using DNA pools followed by construction of
libraries from PCR pools for deep resequencing on NGS platform Illumina
GAII. From the identified variants, categories denoted by an asterisk (*)
were chosen for confirmation by Sanger sequencing of the individual
samples comprising the pool in which the variant was identified.
Additional file 3: Table S2. Primer sequences for PCR amplification of
coding regions of five mTOR pathway genes.
Additional file 4: Table S3. Individual exon coverage data for each
pool of samples.
Additional file 5: Table S4. Summary of reported missense variants in
TSC genes.
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